Conclusions:
The risk of developing non-musculoskeletal manifestations was significantly higher for patients with AS, PsA, and RA than for matched controls. These included not only the well-known manifestations of PsA and AS but also others like manifestations leading to claims for SLE, celiac disease or HS. When managing these systemic arthritides, surveillance for additional immune mediated manifestation is warranted. Acknowledgements: Design, study conduct, and financial support for the study were provided by AbbVie Inc. AbbVie participated in the interpretation of data, review, and approval of the abstract; all authors contributed to the development of the abstract and maintained control over the final content. Medical writing services were provided by Andrew Epstein of Medicus Economics and were funded by AbbVie. Disclosure of Interest: D. Aletaha Grant/research support from: AbbVie, AstraZeneca, BMS, Eli Lilly, Grünenthal, Jansen, Medac, Merck, Mitsubishi Tanabe, Novo Nordisk, Pfizer, and Sanofi/Regeneron, Consultant for: AbbVie, AstraZeneca, BMS, Eli Lilly, Grünenthal, Jansen, Medac, Merck, Mitsubishi Tanabe, Novo Nordisk, Pfizer, and Sanofi/Regeneron, Speakers bureau: AbbVie, AstraZeneca, BMS, Eli Lilly, Grünenthal, Jansen, Medac, Merck, Mitsubishi Tan- Background: Pneumocystis pneumonia (PCP) is a significant cause of morbidity and mortality in patients with rheumatic diseases, especially in the case of patients receiving high-dose steroid treatment. Objectives: To investigate the efficacy and safety of PCP prophylaxis using trimethoprim/sulfamethoxazole (TMP-SMX) in patients with rheumatic disease receiving prolonged, high-dose steroids Methods: This study includes 1522 cases of prolonged (≥4 weeks), high-dose (≥30mg/day prednisone or equivalent) steroid treatment from 1092 patients with any rheumatic diseases during a 12-year period in a single tertiary referral center in South Korea. Of them, prophylactic TMP-SMX was administered in 262 cases (prophylaxis group) with a mean (SD) duration of 229.0 (272.7) days whereas other 1260 cases received no prophylaxis (control group). Primary outcome was 1-year incidence of PCP between the two groups. Secondary outcomes included PCP-related mortality, ICU admission rate, all-cause in-hospital mortality and incidence of any adverse drug reactions (ADRs) of TMP-SMX. To minimize the baseline imbalance between the two groups, we introduced propensity-score matching and performed the same analysis in the post-matched population as a sensitivity analysis. Results: Patients in the prophylaxis group were treated more often with secondary immunosuppressive drugs and had a higher proportion of patients with PCP high-risk diseases (ANCA-associated vasculitis and dermatomyositis) and lymphopenia at baseline. Overall, 30 cases of PCP occurred and resulted in death in 11 cases (36.7%). In the prophylaxis group, only one non-fatal case of PCP occurred. One-year PCP incidence was significantly lower in the prophylaxis group (adjusted HRs=0.096 [0.013-0.719]) (Figure) . TMP-SMX also significantly reduced the PCP-related mortality (adjusted HR=0.101 [0.001-0.809]) whereas ICU admission rate and in-hospital mortality rate were not different between the two groups during the observation. This result was consistent in the sensitivity analysis where same analysis was performed in the post-matched population. Thirty-four cases of ADRs of TMP-SMX occurred, with an incidence rate (95% CI) of 24.2 (17.3-33.0) per 100 person-year. There were two cases of serious ADR (one pancytopenia and one Steven's Johnson syndrome) but they all recovered shortly after the discontinuation of TMP-SMX. The number needed to harm (NNH) of serious ADR was 109 whereas the number needed to treat (NNT) to prevent one case of PCP in the whole population was 52. Conclusions: In patients with rheumatic disease receiving prolonged, high-dose steroid treatment, TMP-SMX prophylaxis significantly lower the incidence of PCP with favorable safety. References: Background: Sarcoidosis is a multisystem, chronic, progressive, granulomatous disease. Sarcoidosis-associated pulmonary hypertension is well described, but not common complication of sarcoidosis 1 . In small scale studies, it has been previously described as a manifestation of advanced disease and was found to be associated with increased morbidity and mortality 2 . Previous studies have shown that treatment may be safe and improve pulmonary hemodynamics in sarcoidosisassociated pulmonary hypertension 3, 4 . However, big data analyses regarding the exact magnitude and prognosis of sarcoidosis-associated pulmonary hypertension are lacking. Objectives: To assess the long-term prognostic significance of sarcoidosisassociated pulmonary hypertension using a big data registry with a 15-year follow-up period. Methods: Utilizing the medical records of Clalit Health Services, the largest HMO in Israel, we extracted a cohort consisted of sarcoidosis patients along with their age-and-sex matched controls. Dates of registration in the medical records of sarcoidosis, pulmonary hypertension and death, as well as anthropometric information and medical comorbidities were extracted from the database. To compare the distribution of variables across the cohort strata, univariate analysis was performed using Chi-square and student t-test. Multivariate analysis using a logistic regression model was used to find variables associated with pulmonary hypertension. Survival analysis using cox proportional hazards method and log-rank test was performed to find variables associated with increased risk of all-cause mortality. Results: The cohort included 3,993 sarcoidosis patients and 19,856 ageand-sex matched controls. The mean age of both groups was 56, and both consisted about 63% females. Pulmonary hypertension was observed among 269 sarcoidosis patients (6.74%) vs. 400 controls (2.01%), p<0.001. In multivariate analysis, sarcoidosis was found to be independently associated with diagnosis of pulmonary hypertension (OR 3.09, 95% CI 2.6-3.67). After more than 15 years of follow-up, 710 (17.8%) of the sarcoidosis patients had died, compared to 2121 (10.7%) of the controls (p<0.001). In multivariate survival analysis, both sarcoidosis and pulmonary hypertension were found to be significantly associated with increased risk to all-cause mortality (HR 1.83, 95% CI 1.66-2.02 and HR 2.32, 95% CI 2.05-2.63, respectively).
Conclusions: Sarcoidosis-associated pulmonary hypertension is associated with poor prognosis. Proper screening methods are recommended to assess whether early identification and treatment may improve life expectancy.
